AHAnhar Hosawi

Anhar Hosawi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anhar Hosawi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Model‐Informed Evaluation of Hydroxyurea Exposure During Lactation

    by Anhar Hosawi, Kei Irie, Min Dong, Julie Ware, Russell Ware, Tomoyuki Mizuno

    Hydroxyurea is a cornerstone therapy for sickle cell anemia; however, evidence guiding its use during lactation remains limited. This study aimed to develop a population pharmacokinetic (PK) model to characterize hydroxyurea disposition in maternal plasma and breast milk, and to quantify infant exposure under clinically relevant breastfeeding scenarios. Population PK modeling was conducted using data from the HELPS study (NCT02990598) with nonlinear mixed‐effects modeling. Maternal plasma PK parameters were first estimated using observed plasma concentration data, followed by estimation of parameters characterizing drug transfer into breast milk. Model‐based stochastic simulations were performed across infant ages 0–9 months to evaluate exposure, expressed as the World Health Organization (WHO)‐recommended relative infant dose (RID), with 10% as the consensus safety threshold. The model diagnostics demonstrated that both plasma and breast milk PK were adequately described by the model. Simulation analyses demonstrated that the estimated RID remained below 10% across all evaluated infant age groups. This integrated plasma‐breast milk population PK model provides a quantitative framework to assess lactational drug exposure. The findings suggest that infant exposure to hydroxyurea through breastfeeding is unlikely to exceed the 10% safety threshold across all age groups (0–9 months), supporting continued maternal therapy during lactation with appropriate clinical oversight.

  • Open Access

    Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

    by Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, et al.

    Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who experience rapid growth and development of organ functions. Although patient's age and body size are often considered when determining pediatric dose, those factors account for only a relatively small part of the variability. Pharmacometrics provides a rigorous framework for characterizing drug behavior, uncovering patient‐specific covariates driving variability, and allows translating insights derived from adults to pediatric populations. Model‐informed precision dosing (MIPD) integrates quantitative pharmacological models to leverage clinical data from patients (e.g., drug concentrations and biomarkers) to predict drug exposure and response, thereby informing optimal dosing strategies to maximize clinical benefits. While MIPD has demonstrated feasibility and clinical benefits, it remains underutilized in routine clinical practice. In this article, we describe the establishment and operation of an MIPD consultation service within an academic children's hospital. Through real‐world examples, we illustrate how precision dosing workflows can be integrated into routine clinical care and highlight key considerations for further dissemination. By sharing our experience, we aim to bridge a critical gap in the literature and provide a practical blueprint for operationalizing MIPD to advance personalized therapy in pediatrics.


  • Optimizing Piperacillin Dosing in Pediatric Liver Transplant Recipients: A Case Series

    by Ronaldo Morales Junior, Anhar Hosawi, Sonya Tang Girdwood, Min Dong, Vanessa D’ Amaro Juodinis, Paschoalina Romano, Pérsio de Almeida Rezende Ebner, Nilo José Coelho Duarte, Daniela Carla de Souza, Silvia Regina Cavani Jorge Santos

    Background: Pathophysiological changes post‐liver transplantation impact the pharmacokinetics and pharmacodynamics of antibiotics. Piperacillin, often used in combination with tazobactam, is a key antibiotic after transplantation to its broad‐spectrum activity, but there is a lack of specific pharmacokinetic data in this population. This study aims to describe the pharmacokinetic parameters and target attainment of piperacillin in pediatric liver transplant recipients.Methods: Patients with preserved renal function (estimated glomerular filtration rate > 50 mL/min/1.73 m2) receiving intravenous piperacillin‐tazobactam at 112.5 mg/kg every 8 h (100 mg piperacillin/12.5 mg tazobactam), with a rapid infusion (0.5–1 h), were included. Two blood samples per child were collected during the same interval within 48 h of starting therapy. A Bayesian approach was applied to estimate individual pharmacokinetic parameters and perform dosing recommendations against Enterococcus spp., Enterobacterales and Pseudomonas aeruginosa.Results: Eight patients with median age of 8 months were included. Median piperacillin clearance and central volume of distribution for the cohort were 11.11 L/h/70 kg and 9.80 L/70 kg, respectively. Seven patients (87.5%) presented with concentrations below the target of 100% fT > MIC. Simulations suggested that these patients required more frequent dosing and extended duration of infusion to ensure target attainment. One patient (12.5%) had trough concentrations that exceed 16 mg/L and could receive a lower daily dose.Conclusions: This case series highlights the importance of personalized therapy in pediatric liver transplant recipients due to the unpredictable and highly variable piperacillin pharmacokinetics in this population.